Centre for Cardiovascular Sciences, Queen Elizabeth Hospital, University of Birmingham, UK.
J Cardiovasc Magn Reson. 2010 Nov 9;12(1):64. doi: 10.1186/1532-429X-12-64.
Cardiac resynchronization therapy (CRT) is an established treatment for patients with symptomatic heart failure, severely impaired left ventricular (LV) systolic dysfunction and a wide (> 120 ms) complex. As with any other treatment, the response to CRT is variable. The degree of pre-implant mechanical dyssynchrony, scar burden and scar localization to the vicinity of the LV pacing stimulus are known to influence response and outcome. In addition to its recognized role in the assessment of LV structure and function as well as myocardial scar, cardiovascular magnetic resonance (CMR) can be used to quantify global and regional LV dyssynchrony. This review focuses on the role of CMR in the assessment of patients undergoing CRT, with emphasis on risk stratification and LV lead deployment.
心脏再同步治疗（CRT）是一种成熟的治疗方法，适用于有症状的心力衰竭、严重左心室（LV）收缩功能障碍和宽（>120ms）复杂的患者。与任何其他治疗方法一样，CRT 的反应是可变的。植入前机械不同步的程度、瘢痕负担和瘢痕在 LV 起搏刺激附近的定位已知会影响反应和结果。除了在评估 LV 结构和功能以及心肌瘢痕方面的公认作用外，心血管磁共振（CMR）还可用于量化整体和局部 LV 不同步。本综述重点介绍了 CMR 在 CRT 患者评估中的作用，重点是风险分层和 LV 导联的部署。
